Indiana Administrative Code › Title 71 - INDIANA HORSE RACING COMMISSION › Article 8 - HUMAN AND EQUINE HEALTH › Rule 1 - Equine Health; Medication Rules › Section 1-4.2 - Threshold levels

Current through July 10, 2024
Authority: IC
				  4-31-3-9
Affected: IC
				  4-31-12
Sec. 4.2.
The official blood (serum or plasma) and urine samples may
				  contain only the following therapeutic medications or their metabolites or
				  analogues, and shall not exceed the threshold concentrations specified in this
				  rule:
(1) The use of acepromazine
				shall be permitted under the following conditions: Not to exceed ten (10)
				nanograms per milliliter of the metabolite, 2-(1-hydroxyethyl) promazine
				sulfoxide (HEPS), in urine.
(2) The
				use of albuterol shall be permitted under the following conditions: Not to
				exceed one (1) nanogram per milliliter of total albuterol (albuterol plus
				conjugates) in urine.
(3) The use
				of betamethasone shall be permitted under the following conditions: Not to
				exceed ten (10) picograms per milliliter of betamethasone in serum or
				plasma.
(4) The use of butorphanol
				shall be permitted under the following conditions: Not to exceed three hundred
				(300) nanograms per milliliter of total (free and conjugated) butorphanol in
				urine or two (2) nanograms per milliliter of free butorphanol in serum or
				plasma.
(5) The use of clenbuterol
				shall be permitted under the following conditions: Not to exceed one hundred
				forty (140) picograms per milliliter clenbuterol in urine or the limit of
				detection (LOD) in serum or plasma.
(6) The use of cetirizine shall be permitted
				under the following conditions: Not to exceed six (6) nanograms per milliliter
				of serum or plasma.
(7) The use of
				cimetidine shall be permitted under the following conditions: Not to exceed
				four hundred (400) nanograms per milliliter of serum or plasma.
(8) The use of dantrolene shall be permitted
				under the following conditions: Not to exceed one hundred (100) picograms per
				milliliter of 5-hydroxydantrolene in serum or plasma.
(9) The use of detomidine shall be permitted
				under the following conditions: Not to exceed two (2) nanograms per milliliter
				of carboxydetomidine in urine or one (1) nanogram per milliliter of detomidine
				in serum or plasma.
(10) The use of
				dexamethasone shall be permitted under the following conditions: Not to exceed
				five (5) picograms per milliliter of dexamethasone in plasma or
				serum.
(11) The use of
				dimethylsulfoxide (DMSO) shall be permitted under the following conditions: Not
				to exceed ten (10) micrograms per milliliter of DMSO in serum or
				plasma.
(12) The use of
				glycopyrrolate shall be permitted under the following conditions: Not to exceed
				three (3) picograms per milliliter of glycopyrrolate in serum or
				plasma.
(13) The use of guaifenesin
				shall be permitted under the following conditions: Not to exceed twelve (12)
				nanograms per milliliter of serum or plasma.
(14) The use of isoflupredone shall be
				permitted under the following conditions: Not to exceed one hundred (100)
				picograms per milliliter of isoflupredone in serum or plasma.
(15) The use of lidocaine shall be permitted
				under the following conditions: Not to exceed twenty (20) picograms per
				milliliter of total 3-hydroxylidocaine (to include conjugates) in serum or
				plasma.
(16) The use of mepivacaine
				shall be permitted under the following conditions: Not to exceed ten (10)
				nanograms per milliliter of total 3-hydroxymepivacaine in urine or the LOD of
				mepivacaine in serum or plasma.
(17) The use of methocarbamol shall be
				permitted under the following conditions: Not to exceed one (1) nanogram per
				milliliter of methocarbamol in serum or plasma.
(18) The use of methylprednisolone shall be
				permitted under the following conditions: Not to exceed one hundred (100)
				picograms per milliliter of methylprednisolone in serum or plasma.
(19) The use of omeprazole shall be permitted
				under the following conditions: Not to exceed ten (10) nanograms per milliliter
				of omeprazole sulfide in serum or plasma.
(20) The use of prednisolone shall be
				permitted under the following conditions: Not to exceed one (1) nanogram per
				milliliter of prednisolone in serum or plasma.
(21) The use of procaine penicillin shall be
				permitted under the following conditions:
(A)
				Not to exceed twenty-five (25) nanograms per milliliter of procaine in serum or
				plasma.
(B) Administration of
				procaine penicillin must be reported to the official veterinarian at the time
				of administration.
(C) Procaine
				penicillin must not be administered after the horse is entered to
				race.
(D) Mandatory surveillance of
				the horse must occur for the six (6) hours immediately preceding the race for
				which the horse is entered by association security at the owner's
				expense.